Abstract Number: 1740 • ACR Convergence 2023
Exploring Disease-Associated DNA Methylome Alterations in Rheumatoid Arthritis: Potential Diagnostic and Prognostic Biomarkers
Background/Purpose: The etiology of rheumatoid arthritis (RA) is not fully understood. It is accepted that RA results from the interplay of genetic and environmental factors.…Abstract Number: 1756 • ACR Convergence 2023
Circulating CD4+CD25+CD127-FoxP3+CD39+ T Cells Predict the Response to Methotrexate Across Basal Disease Activity Strata in Early Rheumatoid Arthritis
Background/Purpose: A subset of human FoxP3+ regulatory T (Treg) cells expresses CD39 (Treg39+) and hydrolyses proinflammatory adenine nucleotides released at inflammatory foci, rendering the antiinflamatory…Abstract Number: 1772 • ACR Convergence 2023
Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients
Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…Abstract Number: 1887 • ACR Convergence 2023
Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients
Background/Purpose: To evaluate the ability of total-body PET (TB-PET) biomarkers to quantify enthesitis in Psoriatic (PsA) and Rheumatoid Arthritis (RA). We hypothesize that objective characterization…Abstract Number: 2034 • ACR Convergence 2023
Assessment of the Immediate and Short-term Impact of an Information Course on Patients’ Knowledge About Rheumatoid Arthritis: Evaluation Using a Self-prepared and Validated Assessment Questionnaire
Background/Purpose: Long-term outcomes in rheumatic diseases can be improved by improving patients' knowledge, beliefs and perception about their disease which can help them in coping…Abstract Number: 2110 • ACR Convergence 2023
Rheumatoid Arthritis and Changes in Pulmonary Function Measures on Spirometry in a Prospective Longitudinal Cohort of Smokers
Background/Purpose: Rheumatoid arthritis (RA) has known extra-articular manifestations that can result in restrictive and obstructive patterns on pulmonary function measures, especially in smokers. However, investigations…Abstract Number: 2126 • ACR Convergence 2023
Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity
Background/Purpose: The Rheumatoid Arthritis Impact of Disease (RAID) is a patient-reported outcome measure (PROM) originating from a EULAR initiative. It might support patient-centred care and…Abstract Number: 2142 • ACR Convergence 2023
Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors
Background/Purpose: In 2021, the FDA concluded that there is an increased risk of serious heart-related events with the Janus Kinase (JAK) inhibitor tofacitinib, which is…Abstract Number: 2158 • ACR Convergence 2023
Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON
Background/Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital capacity (FVC) compared with placebo,…Abstract Number: 2175 • ACR Convergence 2023
Real-World Drug Persistence of GP2015, an Etanercept Biosimilar, in Patients with Rheumatoid Arthritis: Results from the Multi-Country COMPACT Study
Background/Purpose: COMPACT is a multi-country, non-interventional study that evaluated the drug persistence, effectiveness, safety and patient-reported outcomes in patients with rheumatoid arthritis (RA), axial spondyloarthritis…Abstract Number: 2479 • ACR Convergence 2023
Tolerability and Effectiveness of Antifibrotics in Rheumatoid Arthritis-associated Interstitial Lung Disease
Background/Purpose: Nintedanib and pirfenidone are antifibrotic drugs indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and other forms of progressive pulmonary fibrosis. Antifibrotics have…Abstract Number: 2567 • ACR Convergence 2023
An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases
Background/Purpose: There is evidence that extending the interval between COVID-19 vaccination doses is associated with increased immunogenicity and neutralizing activity in healthy individuals (1, 2).…Abstract Number: 0054 • ACR Convergence 2023
RA Monocytes and Monocyte-Derived Macrophages Display Heightened Inflammatory Responses, Reduced Endocytic Capacity and Distinct TET Expression Compared to PsA Monocytes
Background/Purpose: RA and PsA share various pathogenic features, while also displaying significant differences at the clinical, cellular and molecular levels. In this study, we investigate…Abstract Number: 0155 • ACR Convergence 2023
Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA)patients who switch from oral to subcutaneous methotrexate (MTX) may experience better response to treatment due to increased bioavailability, enhanced tolerability, increased…Abstract Number: 0321 • ACR Convergence 2023
Use of Proton Pump Inhibitors and Risk of Hip/knee Joint Replacement Among Patients with Osteoarthritis and Rheumatoid Arthritis
Background/Purpose: Osteoarthritis and rheumatoid arthritis cause significant joint replacement morbidity. Proton pump inhibitors (PPIs) may contribute to chronic inflammation and joint degeneration due to side…
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 188
- Next Page »